Toronto consensus and AGA inflammatory bowel disease parenting working group recommend continuation of anti-TNF treatment throughout pregnancy [10,27] in order to avoid a disease flare, only adjusting last dose timings with final infliximab infusion 6–10 weeks before the estimated date of delivery, and final adalimumab injection 2–3 weeks before delivery [10]. Here, TNF is linked to inflammatory bowel disease.